Stocks Health care XRTX
NASDAQ · Health careXORTX Therapeutics Inc. (XRTX)
It posted a net loss of CA$1.7M. At December 31, 2021 it held CA$18.9M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 20, 2026.
What XORTX Therapeutics Inc. does
XORTX Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XRTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2021 | n/a | -CA$1.7M | n/a | n/a |
| 2021 | n/a | -CA$1.3M | n/a | n/a |
| 2019 | n/a | -CA$629.6K | n/a | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What XORTX Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026
- September 10, 2026
- September 9, 2026
- September 4, 2026
- August 28, 2026
- August 17, 2026
- August 4, 2026
- July 29, 2026
- June 15, 2026
- June 12, 2026
Questions about XRTX
What does XORTX Therapeutics Inc. do?
XORTX Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XRTX.
Is XORTX Therapeutics Inc. profitable?
No. In fiscal 2021 it reported a net loss of CA$1.7M.
When did XORTX Therapeutics Inc. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 20, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 18, 2026.
Similar companies
Compare XRTX with
Follow XRTX
Get an email when XORTX Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow XRTX: get an email when it filesWhere the numbers come from
Financial figures are the values XORTX Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.